ANTIDIABETIC POTENTIAL OF THE OYSTER MUSHROOM PLEUROTUS FLORIDA (MONT.) SINGER
Objective: The present investigation comprises, in vitro antidiabetic activity such as Î±-amylase and Î±-glucosidase inhibitory activities and in vivo antidiabetic activity of methanolic extract of Pleurotus florida.
Methods: The fruiting bodies of Pleurotus florida were obtained from Mushroom Unit, Department of Biology, Gandhigram Rural Institute-Deemed University, Gandhigram, Dindigul, Tamil Nadu, India. Sample preparation, qualitative phytochemical analysis, in vitro antidiabetic activities namely Î±-amylase and Î±-glucosidase inhibitory activity and in vivo antidiabetic activity namely evaluation of alloxan induced diabetic rats were carried out following the methods reported previously.
Results: In vitro and in vivo antidiabetic activity of P. florida exhibited significant results for its Î±-amylase (94.93Â±1.75 % at 1000 Âµg/ml) and Î±-glucosidase inhibitory activity (84.90Â±0.42 % at 1000 Âµg/ml) in a dose-dependent manner. The extract also showed significant antidiabetic activity on in vivo (p<0.05) at the tested dose level (200 mg/kg b. w) this was comparable to Glibenclamide, a standard antidiabetic drug.
Conclusion: The presence of phytochemicals namely phenols, flavonoids, saponins, tannins and terpenoids may be responsible for such antidiabetic activity. These results reveal that P. florida can be used as a potential antidiabetic agent.
2. World Health Organization. Traditional Medicinal Strategy 2002-2005. WHO Publications; 2002. p. 1-6.
3. Li WL, Zheng HC, Bukuru J, Kimpe ND. Natural medicines used in the traditional Chinese medical system for therapy of diabetes mellitus. J Ethnopharmacol 2004;92:1-21.
4. Intekhab A, Barry G. Diabetes mellitus. Clin Dermatol 2006;24:237-46.
5. Berger W. The incidence of severe side effects during therapy with sulphonylureas and biguanide. Hormones Metabol Res 1985;17:111â€5.
6. Rang HP, Dale MM, Ritter JM. The endocrine system pharmacology. Longman Group Ltd. (UK); 1991.
7. Rao BK, Kesavulu MM, Apparao C. Evaluation of the antidiabetic effect of Momordica cynobalaria fruit in alloxan diabetic rats. J Fitoterapia 2003;74:7-13.
8. Cragg GM, Newmann DJ, Snader KM. Natural products in drug discovery and development. J Nat Prod 1997;60:52â€“60.
9. Wong SP, Naidu M, David P, Bakar R, Vikineswary S. Neurogenerative potential of lions mane mushroom, Hericium erinaceus (Bull.: Fr.) Pers., (Higher Basidiomycetes), in the treatment of peripheral nerve injury. Int J Med Mushrooms 2012;14:427â€“46.
10. Prakasam V. Current scenario of mushroom research in India. Indian Phytopath 2012;65:1-11.
11. Prabu M, Kumuthakalavalli R. Antioxidant activity of oyster mushroom (Pleurotus florida [Mont.] Singer) and milky mushroom (Calocybe indica P and C). Int J Curr Pharm Res 2016;8:48-51.
12. Ngai PH, Ng TB. A Hemolysin from the mushroom Pleurotus eryngii. Appl Microbiol Biotechnol 2006;75:1185-91.
13. Hu SH, Chia VC, Lien JL, Chen KS, Lee MY, Wang JC. Antihyperlipidaemic and antioxidant effects of extracts of Pleurotus citrinopileatus. J Agric Food Chem 2006;54:2103-10.
14. Zhang M, Cui SW, Cheung PCK, Wang Q. Antitumor polysaccharides from mushrooms: a review of their isolation process, structural characteristics, and antitumor activity. Trends Food Sci Technol 2007;18:4â€“19.
15. DeFronzo R, Ferrannini E, Alberti G, Zimmet P. International Textbook of Diabetes Mellitus. 4th ed. Wiley-Blackwell Publishers, Chichester, UK; 2015.
16. Packer L, Rfsen P, Tritschler HJ, King GL, Azzi A. Antioxidants in Diabetes Management. Marcel Dekker, New York; 2000.
17. Silva D, Rapior S, Hyde KD, Bahkali AH. Medicinal mushrooms in prevention and control of diabetes mellitus. Fungal Divers 2012;56:1â€“29.
18. Suffness M, Douros J. Drugs of plant origin. In: Methods in Cancer Research, Academic Press; New York. DeVita VT, Busch H. Eds; 1979;26:73â€“126.
19. Harborne JB. Phytochemical methods: a guide to modern techniques of plant analysis. Published by Chapman and Hall, an imprint of Thomson Science, London, UK; 1973.
20. Miller GL. Use of dinitro salicylic acid reagent for determination of reducing sugar. Ann Chem 1959;31:426â€“8.
21. Phuong TM, Lee D, Lee KH. Regression trees for regulatory element identification. Bioinformatics 2004;20:750â€“7.
22. Cheng A, Fantus I. Oral antihyperglycemic therapy for type 2 diabetes mellitus. Can Med Assoc J 2005;172:213â€“6.
23. LoPiparo E, Scheib H, Frei N, Williamson G, Grigorov M, Chou CJ. Flavonoids for controlling starch digestion: structural requirements for inhibiting human Î±-amylase. J Med Chem 2008;51:3555â€“61.
24. Sabitha V, Panneerselvam K, Ramachandran S. In vitro Î±-glucosidase and Î±-amylase enzyme, inhibitory effects in aqueous extracts of Abelmoschus esculentus (L.) moench. Asian Pac J Trop Biomed 2012;2:162â€“4.
25. Lobovitz H. Î±-glucosidase inhibitors. Endocrinol Metabol Clin North Am 1997;26:539â€“51.
26. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes. Sci Rev 2002;287:360â€“72.
27. Laar FA, Lucassen PL, Akkermans RP, Lisdonk EH, Rutten GE, Weel C. Î±-glucosidase inhibitors for patients with type 2 diabetes: results from a cochrane systematic review and meta-analysis. Diabetes Care 2005;28:166â€“75.
28. Thorat K, Patil L, Limaya D, Kadam V. In vitro models for antidiabetic activity assessment. Int J Res Pharm Biomed Sci 2012;3:730â€“2.
29. Jumepaeng T, Prachakool S, Luthria DL, Chanthai S. Determination of antioxidant capacity and Î±â€“amylase inhibitory activity of the essential oils from Citronella grass and Lemongrass. Int J Food Res 2013;20:481â€“5.
30. Bischoff H. Pharmacology of Î±glucosidase inhibitor. Eur J Clin Invest 1994;24:3-10.
31. Silva MCM, Grossi-de-Sa MF, Chrispeels MJ, Togawa RC, Neshich G. Analysis of structural and physicochemical parameters involved in the specificity of binding between Î±-amylases and their inhibitors. Protein Eng 2000;13:167-77.
32. Ali H, Houghton PJ, Soumyanath A. The Î±-amylase inhibitory activity of some Malaysian plants used to treat diabetes with particular reference to Phyllanthus amarus. J Ethnopharmacol 2006;107:449-55.
33. Davis SN, Granner DK. Insulin, oral hypoglycemic activity agents and the pharmacology of endocrine pancreas. In: Goodman and Gilmanâ€™s: The pharmacological basis of therapeutics. 11th ed. McGraw-Hill Medical Publication Division: New York. Brunton et al. Eds; 2001. p. 1706â€“7.
34. Boivin M, Flourie B, Rizza RA, Go VL, DeMagno EP. Gastrointestinal and metabolic effects of amylase inhibition in diabetics. Gastroenterology 1998;94:387-94.
35. Kim JS, Kwon CS, Son KH. Inhibition of alpha glucosidase and amylase by luteolin, a flavonoid. Biosci Biotechnol Biochem 2000;64:2458-61.
36. Lilliooja S, Mott DM, Spraul M, Ferraro R, Foley JE, Ravussin E. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes. Prospective Study of Pima Indians. Engl J Med 1993;329:1988-92.
37. Rajeswari P, Krishnakumari S. The potent antihyperglycemic activity of Calocybe indica in streptozotocin-induced diabetic rat's antihyperglycemic activity of Calocybe indica. Int J Pharm Pharm Sci 2013;5:512â€“5.
38. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813â€“20.
39. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signalling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 2002;23:599â€“622.
40. Jay D, Hitomi H, Griendling KK. Oxidative stress and diabetic cardiovascular complications. Free Radical Biol Med 2006;40:183â€“92.
41. Kowluru RA, Kowluru A, Kanwar M. Small molecular weight G-protein, H-Ras, and retinal endothelial cell apoptosis in diabetes. Mol Cell Biochem 2007;296:69â€“76.
42. Defronzo RA, Ferranini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173â€“94.
43. Wi JE, Kim JK, Youn JH. Reduced glucose clearance as the major determinant of postabsorptive hyperglycemia in rats. Am J Physiol Endocrinol Metab 1998;274:257â€“64.
44. Krishna J, Pandey B, Pathak DB. Characterization of dichotomoceras in the oxfordian of kachchh. J Geol Soc India 2009;74:469â€“79.
45. Khan MA, Rahman MM, Tania M, Uddin MN, Ahmad S. Pleurotus sajor-caju and Pleurotus florida mushrooms improve some extent of the antioxidant systems in the liver of hypercholesterolemic rats. Open Nutraceuticals J 2011;4:20â€“4.
46. Prabu M, Kumuthakalavalli R. In vitro and in vivo antidiabetic activity of Calocybe indica P and C. In: 8th International Conference on Mushroom Biology and Mushroom Products. Organized by Mushroom Society of India; 2014. p. 433â€“7.
47. Johnny I, Okon J. Antidiabetic effect of Pleurotus ostreatus (Jacq ex Fr) Kumm, mushroom on alloxan induced diabetic rats. Indian J Pharm Biol Res 2013;1:31â€“6.